Literature DB >> 15831894

Brain imaging and its implications for studying centrally targeted treatments in irritable bowel syndrome: a primer for gastroenterologists.

D A Drossman1.   

Abstract

Research into brain-gut interactions, and the use of brain imaging, as potential investigative tools for functional gastrointestinal disorders, such as irritable bowel syndrome, is a promising new area. Studies are beginning to identify the structure and function of regions of the brain and their relationships to pain perception, stress, and other psychosocial variables. These imaging modalities may also have diagnostic potential, and perhaps even therapeutic applications, particularly with regard to understanding the benefit of centrally targeted modalities such as antidepressants and psychological treatments.

Entities:  

Mesh:

Year:  2005        PMID: 15831894      PMCID: PMC1774513          DOI: 10.1136/gut.2004.058446

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  38 in total

Review 1.  AGA technical review on irritable bowel syndrome.

Authors:  Douglas A Drossman; Michael Camilleri; Emeran A Mayer; William E Whitehead
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

Review 2.  Brain imaging and functional gastrointestinal disorders: has it helped our understanding?

Authors:  A R Hobson; Q Aziz
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

3.  METHODOLOGICAL ISSUES CONFRONTING PET AND fMRI STUDIES OF COGNITIVE FUNCTION.

Authors:  D N Bub
Journal:  Cogn Neuropsychol       Date:  2000-07-01       Impact factor: 2.468

4.  Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention.

Authors:  H Mertz; V Morgan; G Tanner; D Pickens; R Price; Y Shyr; R Kessler
Journal:  Gastroenterology       Date:  2000-05       Impact factor: 22.682

5.  Regional cerebral activity in normal and pathological perception of visceral pain.

Authors:  D H Silverman; J A Munakata; H Ennes; M A Mandelkern; C K Hoh; E A Mayer
Journal:  Gastroenterology       Date:  1997-01       Impact factor: 22.682

6.  Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation.

Authors:  B D Naliboff; S W Derbyshire; J Munakata; S Berman; M Mandelkern; L Chang; E A Mayer
Journal:  Psychosom Med       Date:  2001 May-Jun       Impact factor: 4.312

7.  Does rejection hurt? An FMRI study of social exclusion.

Authors:  Naomi I Eisenberger; Matthew D Lieberman; Kipling D Williams
Journal:  Science       Date:  2003-10-10       Impact factor: 47.728

Review 8.  Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception.

Authors:  W E Whitehead; O S Palsson
Journal:  Gastroenterology       Date:  1998-11       Impact factor: 22.682

9.  The neural correlates of placebo effects: a disruption account.

Authors:  Matthew D Lieberman; Johanna M Jarcho; Steve Berman; Bruce D Naliboff; Brandall Y Suyenobu; Mark Mandelkern; Emeran A Mayer
Journal:  Neuroimage       Date:  2004-05       Impact factor: 6.556

10.  Regional brain activation in response to rectal distension in patients with irritable bowel syndrome and the effect of a history of abuse.

Authors:  Yehuda Ringel; Douglas A Drossman; Timothy G Turkington; Barbara Bradshaw; Thomas C Hawk; Shrikant Bangdiwala; R Edward Coleman; William E Whitehead
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

View more
  13 in total

Review 1.  Central pain mechanisms in chronic pain states--maybe it is all in their head.

Authors:  Kristine Phillips; Daniel J Clauw
Journal:  Best Pract Res Clin Rheumatol       Date:  2011-04       Impact factor: 4.098

2.  Treatment of Functional GI Disorders With Psychotropic Medicines: A Review of Evidence With a Practical Approach.

Authors:  Syed I M Thiwan; Douglas A Drossman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-09

Review 3.  The narcotic bowel syndrome: a recent update.

Authors:  Douglas Drossman; Eva Szigethy
Journal:  Am J Gastroenterol Suppl       Date:  2014-09-10

4.  Brain activity following esophageal acid infusion using positron emission tomography.

Authors:  Shigeyuki Kobayashi; Yasuhiko Abe; Manabu Tashiro; Tomoyuki Koike; Katsunori Iijima; Akira Imatani; Shuichi Ohara; Satoshi Watanabe; Shin Fukudo; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2010-11-21       Impact factor: 5.742

5.  Maladaptive Coping and Depressive Symptoms Partially Explain the Association Between Family Stress and Pain-Related Distress in Youth With IBD.

Authors:  Bonney Reed-Knight; Miranda A L van Tilburg; Rona L Levy; Shelby L Langer; Joan M Romano; Tasha B Murphy; Melissa M DuPen; Andrew D Feld
Journal:  J Pediatr Psychol       Date:  2018-01-01

Review 6.  Functional findings in irritable bowel syndrome.

Authors:  Iris Posserud; Amanda Ersryd; Magnus Simrén
Journal:  World J Gastroenterol       Date:  2006-05-14       Impact factor: 5.742

7.  The narcotic bowel syndrome: clinical features, pathophysiology, and management.

Authors:  David M S Grunkemeier; Joseph E Cassara; Christine B Dalton; Douglas A Drossman
Journal:  Clin Gastroenterol Hepatol       Date:  2007-10       Impact factor: 11.382

8.  Not all side effects associated with tricyclic antidepressant therapy are true side effects.

Authors:  Syed Thiwan; Douglas A Drossman; Carolyn B Morris; Chris Dalton; Brenda B Toner; Nicholas E Diamant; J B Hu; William E Whitehead; Jane Leserman; Shrikant I Bangdiwala
Journal:  Clin Gastroenterol Hepatol       Date:  2008-11-21       Impact factor: 11.382

Review 9.  Descending pain modulation in irritable bowel syndrome (IBS): a systematic review and meta-analysis.

Authors:  Rosemary J Chakiath; Philip J Siddall; John E Kellow; Julia M Hush; Mike P Jones; Anna Marcuzzi; Paul J Wrigley
Journal:  Syst Rev       Date:  2015-12-10

10.  Correlation between gastrointestinal hormones and anxiety-depressive states in irritable bowel syndrome.

Authors:  Baojuan Han
Journal:  Exp Ther Med       Date:  2013-07-09       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.